Mezagitamab for Immune Thrombocytopenic Purpura
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if mezagitamab can stabilize platelet counts in adults with immune thrombocytopenia (ITP), a condition where the immune system mistakenly attacks platelets, causing easy bruising or bleeding. Participants will receive either mezagitamab, an experimental treatment, or a placebo, a look-alike without active ingredients, through injections under the skin. Individuals with ITP for at least a year, who have tried other treatments but still experience low platelet counts, might be suitable for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking treatment.
Do I have to stop taking my current medications for the trial?
You may continue your current ITP treatment during the trial if the dose and frequency have been stable for at least 4 weeks before starting the trial and are expected to remain stable throughout the trial. However, certain medications like anticoagulants and specific immunosuppressive agents must be stopped before the trial.
Is there any evidence suggesting that mezagitamab is likely to be safe for humans?
Research has shown that mezagitamab is generally safe for people with immune thrombocytopenia (ITP). Studies have found that mezagitamab can significantly increase platelet counts, benefiting those with ITP. Most people tolerate it well, experiencing no serious side effects.
In a previous study, ITP patients received mezagitamab and showed positive safety results. Most participants managed the treatment well without major problems. Additionally, ongoing research aims to ensure mezagitamab's safety over longer periods.
Current data and studies suggest that mezagitamab is a safe option for managing ITP.12345Why do researchers think this study treatment might be promising?
Researchers are excited about mezagitamab for treating Immune Thrombocytopenic Purpura (ITP) because it offers a novel approach compared to standard treatments like corticosteroids, immunoglobulins, or thrombopoietin receptor agonists. Mezagitamab is unique because it is a monoclonal antibody administered via a simple subcutaneous injection, which is more convenient for patients. Unlike traditional therapies that often have broad immune-suppressing effects, mezagitamab specifically targets immune pathways implicated in ITP, potentially reducing side effects and improving efficacy. This targeted mechanism of action is what makes mezagitamab a promising candidate in the treatment landscape for ITP.
What evidence suggests that mezagitamab might be an effective treatment for immune thrombocytopenic purpura?
Research has shown that mezagitamab, which participants in this trial may receive, may help treat primary immune thrombocytopenia (ITP). In a previous study, patients who took mezagitamab had more platelets in their blood compared to those who took a placebo. Platelets are important because they help stop bleeding. Mezagitamab also led to lasting improvements in platelet levels and reduced ITP symptoms. This suggests that mezagitamab could be a good option, especially for people who haven't had success with other treatments.12467
Who Is on the Research Team?
Study Director
Principal Investigator
Takeda
Are You a Good Fit for This Trial?
Adults with chronic primary immune thrombocytopenia (ITP) who haven't had enough improvement from at least one first-line therapy like corticosteroids and one second-line treatment. They should have a stable dose of any current ITP treatments, not be pregnant, and have a low platelet count (<30,000/μL).Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive mezagitamab or placebo subcutaneously once weekly for up to 6 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment with open-label mezagitamab if eligible
What Are the Treatments Tested in This Trial?
Interventions
- Mezagitamab
Trial Overview
The trial is testing mezagitamab—a medication given under the skin—against a placebo to see if it can stabilize platelet counts in adults with ITP over six months. Participants will make several clinic visits and may join a follow-up study.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Participants will receive mezagitamab injection, SC, once weekly (QW). They will receive 8 weekly doses, followed by 8 weekly doses off, and then receive 8 more weekly doses.
Participants will receive mezagitamab placebo-matching injection, SC, QW. They will receive 8 weekly doses, followed by 8 weekly doses off, and then receive 8 more weekly doses.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Takeda
Lead Sponsor
Dr. Naoyoshi Hirota
Takeda
Chief Medical Officer since 2020
MD from University of Tokyo
Christophe Weber
Takeda
Chief Executive Officer since 2015
PhD in Molecular Biology from Université de Montpellier
Citations
1.
takeda.com
takeda.com/newsroom/newsreleases/2024/late-breaking-data-from-phase-2b-study-of-mezagitamab/Takeda Unveils Promising Phase 2b Results for ...
The Phase 2b trial results demonstrated that mezagitamab treatment improved platelet response compared to placebo, across all three dose levels of mezagitamab ...
NCT06722235 | A Study of Mezagitamab in Adults With ...
The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously [SC]), is effective in keeping the platelet count of ...
Mezagitamab and the future of ITP treatment
While current treatments are reasonably effective for many, around 20-30% of patients either do not respond or cannot tolerate them.
4.
2minutemedicine.com
2minutemedicine.com/takedas-mezagitamab-delivers-sustained-platelet-boost-in-phase-2-clinical-trials-for-treatment-of-immune-thrombocytopenia-purpura/Takeda's Mezagitamab Delivers Sustained Platelet Boost ...
Mezagitamab achieved a sustained platelet response and symptomatic relief in patients treated for chronic ITP.
A Study of Mezagitamab in Adults With Chronic Primary ...
The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously [SC]), is effective in keeping the platelet count of ...
Mezagitamab in Patients With Immune Thrombocytopenia
Results showed that through week 16 all groups experienced an increased duration of platelet response with a mean increase with mezagitamab over ...
NCT06948318 | A Continuation Study of Mezagitamab in ...
The main aim of this study is to check how safe mezagitamab is and how well it is tolerated by adults with chronic primary ITP, if given over a longer time.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.